Background : VEGF play a significant role in the pathogenesis of chronic myeloid leukemia .
Objective :(1).Assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia(CML). (2). Study the effect of Hydroxyurea and Imatinib on serum VEGF level.
Material and Methods : A total of 40 cases of chronic myeloid leukemia (CML) and 20 age and sex matched healthy controls were included in this study. The patients were divided into three subcategory: Untreated cases (which did not receive any treatment);patients who were treated with Hydroxyurea and patients who were treated with Imatinib Mesylate . 5 ml of blood was collected , were centrifuged at 5000 rpm for 10 minutes and stored at - 20°C until assay.
Results : On comparing the various subgroups with control, the values was 726.61 ±199.67 pg/ml in Untreated group. It was 573.53 ± 213.423 pg/ml in Hydroxyurea group and 530.00±180.96 pg/ml in Imatinib group. Fresh cases had significantly elevated VEGF value (P value < 0.001) . VEGF level significantly elevated in Untreated cases when compared to treated groups either hydroxyurea (p=0.02) or Imatinib (p=0.019). There was no significant difference between Hydroxyurea and Imatinib groups.
Conclusion : This study suggest that VEGF play a significant role in the pathogenesis of chronic myeloid leukemia. Understanding this may help in designing new therapeutic strategies(antiangiogenic agents) for this dreaded disease.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
